US Stock MarketDetailed Quotes

VYGR Voyager Therapeutics

Watchlist
  • 4.230
  • -0.150-3.42%
Close Feb 14 16:00 ET
  • 4.240
  • +0.010+0.24%
Post 19:33 ET
231.07MMarket Cap6.41P/E (TTM)

About Voyager Therapeutics Company

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Company Profile

SymbolVYGR
Company NameVoyager Therapeutics
Listing DateNov 11, 2015
Issue Price14.00
Founded2013
CEODr. Alfred W. Sandrock, Jr,M.D.,PhD
MarketNASDAQ
Employees162
Fiscal Year Ends12-31
Address75 Hayden Avenue
CityLexington
ProvinceMassachusetts
CountryUnited States of America
Zip Code02421
Phone1-857-259-5340

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Alfred W. Sandrock, Jr,M.D.,PhD
  • Director, President and Chief Executive Officer
  • 3.17M
  • Robin Swartz
  • Chief Operating Officer
  • 1.38M
  • Dr. Nathan Jorgensen, M.B.A.,PhD
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Toby Ferguson
  • Chief Medical Officer
  • --
  • Dr. Todd Carter, PhD
  • Chief Scientific Officer
  • --
  • Jacquelyn Fahey Sandell, J.D.
  • Chief Legal Officer
  • 1.68M
  • Michael J. Higgins
  • Chairman of the Board
  • 281.28K
  • Dr. Jude Onyia, PhD
  • Director
  • 452.32K
  • Nancy Vitale
  • Independent Director
  • 255.28K
  • Dr. Steven E. Hyman, M.D.
  • Independent Director
  • 255.78K
  • Dr. George A. Scangos,PhD
  • Independent Director
  • 559.79K
  • James A. Geraghty
  • Independent Director
  • 263.78K
  • Dr. Grace E. Colon, PhD
  • Independent Director
  • 432.23K
  • Dr. Glenn F. Pierce, M.D.,PhD
  • Independent Director
  • 248.78K
  • Dr. Catherine J. Mackey, PhD
  • Independent Director
  • 250.78K

Trending Stocks

Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More